PMV Pharmaceuticals, Inc.

Contributing Author

Recent Articles by PMV Pharmaceuticals, Inc.

14 hours	PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights PMVP +7.19% GlobeNewswire
Feb-26	New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors PMVP +22.32% GlobeNewswire
Nov-12	PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights PMVP +6.77% GlobeNewswire
Oct-24	PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PMVP GlobeNewswire
Oct-13	PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PMVP +7.58% PMVP GlobeNewswire
Sep-10	PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PMVP -20.63% GlobeNewswire
Aug-07	PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights PMVP GlobeNewswire
May-23	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences PMVP GlobeNewswire
May-09	PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights PMVP GlobeNewswire